glp-1 obesity drug news today september 2025 ISPOR 2025: Exploring reasons for discontinuation The first of three of

Doctors usually prescribe a lower dose to start with and work up to a full-strength dose over several months to minimize side effects

Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes

In summary, tirzepatide was noninferior and superior to semaglutide with respect to the reduction of HbA1c from baseline to 40 weeks (54, 71)

Inflammation in Parkinsons Disease: Mechanisms and Therapeutic Implications

The SURPASS-1 trial investigated the efficacy and safety of the three doses of 5, 10, or 15 mg tirzepatide in drug-nave patients with T2D who were not sufficiently controlled with a lifestyle intervention with diet and exercise versus placebo (70)

M.JuhlC